BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Huang DQ, Singal AG, Kono Y, Tan DJ, El-serag HB, Loomba R. Changing global epidemiology of liver cancer from 2010 to 2019: NASH is the fastest growing cause of liver cancer. Cell Metabolism 2022. [DOI: 10.1016/j.cmet.2022.05.003] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 17.0] [Reference Citation Analysis]
Number Citing Articles
1 He YF, Cheng K, Zhong ZT, Hou XL, An CZ, Chen W, Liu B, Zhao YD. Simultaneous labeling and multicolor fluorescence imaging of multiple immune cells on liver frozen section by polychromatic quantum dots below freezing points. J Colloid Interface Sci 2023;636:42-54. [PMID: 36621128 DOI: 10.1016/j.jcis.2022.12.165] [Reference Citation Analysis]
2 Ji L, Deng H, Xue H, Wang J, Hong K, Gao Y, Kang X, Fan G, Huang W, Zhan J, You Y. Research progress regarding the effect and mechanism of dietary phenolic acids for improving nonalcoholic fatty liver disease via gut microbiota. Compr Rev Food Sci Food Saf 2023. [PMID: 36717374 DOI: 10.1111/1541-4337.13106] [Reference Citation Analysis]
3 Yokoo T, Masaki N, Parikh ND, Lane BF, Feng Z, Mendiratta-Lala M, Lee CH, Khatri G, Marsh TL, Shetty K, Dunn CT, Al-Jarrah T, Aslam A, Davenport MS, Gopal P, Rich NE, Lok AS, Singal AG. Multicenter Validation of Abbreviated MRI for Detecting Early-Stage Hepatocellular Carcinoma. Radiology 2023;:220917. [PMID: 36692401 DOI: 10.1148/radiol.220917] [Reference Citation Analysis]
4 Fernández-Tussy P, Sun J, Cardelo MP, Price NL, Goedeke L, Xirouchaki CE, Yang X, Pastor-Rojo O, Bennett AM, Tiganis T, Suárez Y, Fernández-Hernando C. Hepatocyte-specific miR-33 deletion attenuates NAFLD-NASH-HCC progression. bioRxiv 2023:2023. [PMID: 36711578 DOI: 10.1101/2023.01.18.523503] [Reference Citation Analysis]
5 Teng PC, Huang DQ, Lin TY, Noureddin M, Yang JD. Diabetes and Risk of Hepatocellular Carcinoma in Cirrhosis Patients with Nonalcoholic Fatty Liver Disease. Gut Liver 2023;17:24-33. [PMID: 36530125 DOI: 10.5009/gnl220357] [Reference Citation Analysis]
6 Zeng RW, Yong JN, Tan DJH, Fu CE, Lim WH, Xiao J, Chan KE, Tan C, Goh XL, Chee D, Syn N, Tan EX, Muthiah MD, Ng CH, Tamaki N, Lee SW, Kim BK, Nguyen MH, Loomba R, Huang DQ. Meta-analysis: Chemoprevention of hepatocellular carcinoma with statins, aspirin and metformin. Aliment Pharmacol Ther 2023. [PMID: 36625733 DOI: 10.1111/apt.17371] [Reference Citation Analysis]
7 Huang DQ, Mathurin P, Cortez-Pinto H, Loomba R. Global epidemiology of alcohol-associated cirrhosis and HCC: trends, projections and risk factors. Nat Rev Gastroenterol Hepatol 2023;20:37-49. [PMID: 36258033 DOI: 10.1038/s41575-022-00688-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Luo PQ, Ye ZH, Zhang LX, Song ED, Wei ZJ, Xu AM, Lu Z. Prognostic factors for disease-free survival in postoperative patients with hepatocellular carcinoma and construction of a nomogram model. World J Clin Cases 2022; 10(36): 13250-13263 [DOI: 10.12998/wjcc.v10.i36.13250] [Reference Citation Analysis]
9 Cholankeril G, El-Serag HB. Current Challenges and Future Direction in Surveillance for Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease. Semin Liver Dis 2022. [PMID: 36216350 DOI: 10.1055/a-1957-8540] [Reference Citation Analysis]
10 Oura K, Morishita A, Tani J, Masaki T. Antitumor Effects and Mechanisms of Metabolic Syndrome Medications on Hepatocellular Carcinoma. J Hepatocell Carcinoma 2022;9:1279-98. [PMID: 36545268 DOI: 10.2147/JHC.S392051] [Reference Citation Analysis]
11 Bernardi L, Roesel R, Vagelli F, Majno-Hurst P, Cristaudi A. Imaging based body composition profiling and outcomes after oncologic liver surgery. Front Oncol 2022;12:1007771. [PMID: 36568174 DOI: 10.3389/fonc.2022.1007771] [Reference Citation Analysis]
12 Younes M, Zhang L, Fekry B, Eckel-Mahan K. Expression of p-STAT3 and c-Myc correlates with P2-HNF4α expression in nonalcoholic fatty liver disease (NAFLD). Oncotarget 2022;13:1308-13. [PMID: 36473131 DOI: 10.18632/oncotarget.28324] [Reference Citation Analysis]
13 Wang M, Singal AG, Parikh N, Kono Y, Marrero J, Mehta A. A Biomarker Panel Based upon AFP, Fucosylated Kininogen and PEG-Precipitated IgG Is Highly Accurate for the Early Detection Hepatocellular Carcinoma in Patients with Cirrhosis in Phase II and Phase III Biomarker Evaluation. Cancers (Basel) 2022;14. [PMID: 36497452 DOI: 10.3390/cancers14235970] [Reference Citation Analysis]
14 Gallage S, Avila JEB, Ramadori P, Focaccia E, Rahbari M, Ali A, Malek NP, Anstee QM, Heikenwalder M. A researcher's guide to preclinical mouse NASH models. Nat Metab 2022;4:1632-49. [PMID: 36539621 DOI: 10.1038/s42255-022-00700-y] [Reference Citation Analysis]
15 Wong RJ, Jayasekera C, Jones P, Kanwal F, Singal AG, Ahmed A, Taglienti R, Younossi Z, Kulik L, Mehta N. An Open-Access, Interactive Decision-Support Tool to Facilitate Guideline-Driven Care for Hepatocellular Carcinoma. Gastroenterology Res 2022;15:297-307. [PMID: 36660470 DOI: 10.14740/gr1573] [Reference Citation Analysis]
16 Luo Y, Jiao Q, Chen Y. Targeting endoplasmic reticulum stress-the responder to lipotoxicity and modulator of non-alcoholic fatty liver diseases. Expert Opin Ther Targets 2022;26:1073-85. [PMID: 36657744 DOI: 10.1080/14728222.2022.2170780] [Reference Citation Analysis]
17 Tuero C, Becerril S, Ezquerro S, Neira G, Frühbeck G, Rodríguez A. Molecular and cellular mechanisms underlying the hepatoprotective role of ghrelin against NAFLD progression. J Physiol Biochem 2022. [DOI: 10.1007/s13105-022-00933-1] [Reference Citation Analysis]
18 Ajmera V, Cepin S, Tesfai K, Hofflich H, Cadman K, Lopez S, Madamba E, Bettencourt R, Richards L, Behling C, Sirlin CB, Loomba R. A prospective study on the prevalence of NAFLD, advanced fibrosis, cirrhosis and hepatocellular carcinoma in people with type 2 diabetes. J Hepatol 2022:S0168-8278(22)03302-5. [PMID: 36410554 DOI: 10.1016/j.jhep.2022.11.010] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
19 Tay PWL, Ng CH, Lin SY, Chin YH, Xiao J, Lim WH, Lim SY, Fu CE, Chan KE, Quek J, Tan DJH, Chew N, Syn N, Keitoku T, Tamaki N, Siddiqui MS, Noureddin M, Muthiah M, Huang DQ, Loomba R. Placebo Adverse Events in Non-alcoholic Steatohepatitis Clinical Trials: A Pooled Analysis of 2,944 Participants. Am J Gastroenterol 2022. [PMID: 36191268 DOI: 10.14309/ajg.0000000000002042] [Reference Citation Analysis]
20 Farah M, Anugwom C, Ferrer JD, Baca EL, Mattos AZ, Possebon JPP, Arrese M, Prieto J, Balderramo D, Carrera E, Debes JD. Changing epidemiology of hepatocellular carcinoma in South America: A report from the South American liver research network. Ann Hepatol 2022;28:100876. [PMID: 36400386 DOI: 10.1016/j.aohep.2022.100876] [Reference Citation Analysis]
21 Liu YB, Chen MK. Epidemiology of liver cirrhosis and associated complications: Current knowledge and future directions. World J Gastroenterol 2022; 28(41): 5910-5930 [DOI: 10.3748/wjg.v28.i41.5910] [Reference Citation Analysis]
22 Rasha F, Paul S, Simon TG, Hoshida Y. Hepatocellular Carcinoma Chemoprevention with Generic Agents. Semin Liver Dis 2022;42:501-13. [PMID: 36104114 DOI: 10.1055/a-1942-6693] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
23 Huang DQ, Downes M, Evans RM, Witztum JL, Glass CK, Loomba R. Shared Mechanisms between Cardiovascular Disease and NAFLD. Semin Liver Dis 2022;42:455-64. [PMID: 36008083 DOI: 10.1055/a-1930-6658] [Reference Citation Analysis]
24 Chien SC, Lin YJ, Lee CT, Chiu YC, Chou TC, Chiu HC, Tsai HW, Su CM, Yang TH, Chiang HC, Tsai WC, Yang KC, Cheng PN. Higher Risk of Tumor Recurrence in NASH-Related Hepatocellular Carcinoma Following Curative Resection. Viruses 2022;14. [PMID: 36366525 DOI: 10.3390/v14112427] [Reference Citation Analysis]
25 Green CD, Spiegel S. Preclinical models of non-alcoholic steatohepatitis leading to hepatocellular carcinoma. Adv Biol Regul 2022;87:100925. [PMID: 36706611 DOI: 10.1016/j.jbior.2022.100925] [Reference Citation Analysis]
26 Tan DJH, Quek SXZ, Yong JN, Suresh A, Koh KXM, Lim WH, Quek J, Tang A, Tan C, Nah B, Tan E, Keitoku T, Muthiah MD, Syn N, Ng CH, Kim BK, Tamaki N, Ho CSH, Loomba R, Huang DQ. Global prevalence of depression and anxiety in patients with hepatocellular carcinoma: Systematic review and meta-analysis. Clin Mol Hepatol 2022;28:864-75. [PMID: 36263668 DOI: 10.3350/cmh.2022.0136] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
27 Tamaki N, Tada T, Kurosaki M, Yasui Y, Ochi H, Mashiba T, Sakamoto A, Marusawa H, Narita R, Uchida Y, Akahane T, Kondo M, Mori N, Takaki S, Tsuji K, Kobashi H, Kusakabe A, Furuta K, Arai H, Nonogi M, Ogawa C, Sato T, Tamada T, Nakamura S, Hasebe C, Tsuchiya K, Izumi N. Optimal threshold of alpha-fetoprotein response in patients with unresectable hepatocellular carcinoma treated with atezolizumab and bevacizumab. Invest New Drugs 2022. [PMID: 36152108 DOI: 10.1007/s10637-022-01303-w] [Reference Citation Analysis]
28 Wang X. Challenges and opportunities in nonalcoholic steatohepatitis. Medical Review 2022;0. [DOI: 10.1515/mr-2022-0024] [Reference Citation Analysis]
29 Brozzetti S, D’alterio C, Bini S, Antimi J, Rocco B, Fassari A, Lucatelli P, Nardis P, Di Martino M, De Sanctis GM, Corona M, Bagni O, Cortesi E, Bezzi M, Catalano C. Surgical Resection Is Superior to TACE in the Treatment of HCC in a Well Selected Cohort of BCLC-B Elderly Patients—A Retrospective Observational Study. Cancers 2022;14:4422. [DOI: 10.3390/cancers14184422] [Reference Citation Analysis]
30 Huang DQ, Sharpton SR, Amangurbanova M, Tamaki N, Sirlin CB, Loomba R; Nafld Research Study Group. Clinical Utility of Combined MRI-PDFF and ALT Response in Predicting Histologic Response in Nonalcoholic Fatty Liver Disease. Clin Gastroenterol Hepatol 2022:S1542-3565(22)00832-1. [PMID: 36075503 DOI: 10.1016/j.cgh.2022.08.036] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
31 Tan DJH, Setiawan VW, Ng CH, Lim WH, Muthiah MD, Tan EX, Dan YY, Roberts LR, Loomba R, Huang DQ. Global burden of liver cancer in males and females: Changing etiological basis and the growing contribution of NASH. Hepatology 2022. [PMID: 36037274 DOI: 10.1002/hep.32758] [Cited by in Crossref: 5] [Article Influence: 5.0] [Reference Citation Analysis]
32 Zunica ERM, Heintz EC, Axelrod CL, Kirwan JP. Obesity Management in the Primary Prevention of Hepatocellular Carcinoma. Cancers (Basel) 2022;14:4051. [PMID: 36011044 DOI: 10.3390/cancers14164051] [Reference Citation Analysis]
33 De Ponti F, Scott C. Modulating hepatic macrophages with annexin A1 in non-alcoholic steatohepatitis. Clinical Science 2022;136:1111-5. [DOI: 10.1042/cs20220258] [Reference Citation Analysis]
34 Craciun A, Cortez-pinto H. Alarming increase of NASH as cause of liver cancer. Cell Reports Medicine 2022;3:100723. [DOI: 10.1016/j.xcrm.2022.100723] [Reference Citation Analysis]
35 Singal AG, Nagar SP, Hitchens A, Davis KL, Iyer S. Real-world effectiveness of lenvatinib monotherapy in previously treated unresectable hepatocellular carcinoma in US clinical practice. Cancer Rep (Hoboken) 2023;6:e1679. [PMID: 35822407 DOI: 10.1002/cnr2.1679] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]